Company Profiles

driven by the PitchBook Platform

Labcyte

Labcyte
2000 FOUNDED
PRIVATE STATUS
51-200 EMPLOYEES
2ndary - Private LATEST DEAL TYPE
$78.9M TOTAL AMOUNT RAISED
11 INVESTORS
Description

Developer of an acoustic droplet ejection (ADE) technology designed to enhance personalized medicine programs. The company's acoustic droplet ejection (ADE) technology uses acoustic energy to transfer precise amounts of fluids without touching them, which can improve data quality and reliability and focuses on ultrasonic acoustic energy into a fluid sample to eject droplets of liquid from open wells, enabling healthcare industry to streamline DNA/RNA diagnostic testing, optimize drug discovery pipelines and accelerate life science research.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Devices and Supplies
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
170 Rose Orchard Way
San Jose, CA 95134
United States

+1 (408) 747-2000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Labcyte’s full profile, request a free trial.

Labcyte Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private $78.9M Completed Generating Revenue
8. Later Stage VC (Series E) 03-Jan-2017 000 000.00 00000 Completed Generating Revenue
7. Debt - General 06-May-2015 0000 000.00 Completed Generating Revenue
6. Later Stage VC (Series D) 19-Sep-2013 00.000 000.00 000.00 Completed Generating Revenue
5. Grant 09-Nov-2011 00000 000.00 Completed Generating Revenue
4. Debt - General 12-Nov-2009 00.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 13-Mar-2008 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 09-Jul-2002 $22.5M $27.8M $52M Completed Startup
1. Early Stage VC (Series A) 28-Jun-2002 $5.25M $5.25M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Labcyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series D 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.00
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 28,137,025 $0.010000 $0.06 $0.8 $0.8 1x $0.8 19.56%
Series A 10,277,815 $0.010000 $0.04 $0.54 $0.54 1x $0.54 7.14%
To view this company’s complete Cap Table request access »

Labcyte Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Abingworth Management Venture Capital Minority 000 0000 000000 0
Alloy Ventures Venture Capital Minority 000 0000 000000 0
Cross Atlantic Partners Venture Capital Minority 000 0000 000000 0
DBL Partners Venture Capital Minority 000 0000 000000 0
Delphi Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Labcyte Executive Team (12)

Name Title Board
Seat
Contact
Info
Mark Fischer-Colbrie Chief Executive Officer, Board Member and President
Tammy Cameron Chief Financial Officer
Richard Ellson Co-Founder, Chief Technology Officer & Board Member
Jurgen Osing Ph.D Managing Director
Randy Moon Director, Materials
You’re viewing 5 of 12 executives. Get the full list »

Labcyte Board Members (7)

Name Representing Role Since Contact
Info
Craig Taylor Alloy Ventures Board Member 000 0000
Jonathan MacQuitty Ph.D Abingworth Management Board Member 000 0000
Joseph Keegan Ph.D Self Chairman 000 0000
Joseph Smith Self Board Member 000 0000
Mark Fischer-Colbrie Labcyte Chief Executive Officer, Board Member and President 000 0000

1 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »